<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">38689</article-id><article-id pub-id-type="doi">10.7554/eLife.38689</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>PIP<sub>2</sub> depletion promotes TRPV4 channel activity in mouse brain capillary endothelial cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-113900"><name><surname>Harraz</surname><given-names>Osama F</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2061-1100</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-71590"><name><surname>Longden</surname><given-names>Thomas Andrew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-114308"><name><surname>Hill-Eubanks</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-113901"><name><surname>Nelson</surname><given-names>Mark T</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6608-8784</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="other" rid="par-12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of Vermont</institution>, <addr-line><named-content content-type="city">Burlington</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-25647"><name><surname>Csanády</surname><given-names>László</given-names></name><role>Reviewing editor</role><aff><institution>Semmelweis University</institution>, <country>Hungary</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Mark.Nelson@uvm.edu</email> (MN);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>08</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e38689</elocation-id><history><date date-type="received"><day>26</day><month>05</month><year>2018</year></date><date date-type="accepted"><day>06</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Harraz et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Harraz et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-38689-v1.pdf"/><abstract><p>We recently reported that the inward-rectifier Kir2.1 channel in brain capillary endothelial cells (cECs) plays a major role in neurovascular coupling (NVC) by mediating a neuronal activity-dependent, propagating vasodilatory (hyperpolarizing) signal. We further demonstrated that Kir2.1 activity is suppressed by depletion of plasma membrane phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>). Whether cECs express depolarizing channels that intersect with Kir2.1-mediated signaling remains unknown. Here, we report that Ca<sup>2+</sup>/Na<sup>+</sup>-permeable TRPV4 (transient receptor potential vanilloid 4) channels are expressed in cECs and are tonically inhibited by PIP<sub>2</sub>. We further demonstrate that depletion of PIP<sub>2</sub> by agonists, including putative NVC mediators, that promote PIP<sub>2</sub> hydrolysis by signaling through G<sub>q</sub>-protein-coupled receptors (G<sub>q</sub>PCRs) caused simultaneous disinhibition of TRPV4 channels and suppression of Kir2.1 channels. These findings collectively support the concept that G<sub>q</sub>PCR activation functions as a molecular switch to favor capillary TRPV4 activity over Kir2.1 signaling, an observation with potentially profound significance for the control of cerebral blood flow.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>Postdoctoral fellowship 17POST33650030</award-id><principal-award-recipient><name><surname>Harraz</surname><given-names>Osama F</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R37-DK-053832</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>7UM-HL-1207704</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-HL-131181</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>Scientist Development Grant 17SDG33670237</award-id><principal-award-recipient><name><surname>Longden</surname><given-names>Thomas Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01-HL-095488</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>4P20 GM103644/4-5 to the Vermont Center on Behavior and Health</award-id><principal-award-recipient><name><surname>Longden</surname><given-names>Thomas Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>The Totman Medical Research Trust</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>European Union's Horizon 2020 Research and Innovation Programme</institution></institution-wrap></funding-source><award-id>Grant agreement No 666881 SVDs@target</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30-GM-103498 to the COBRE imaging facility at UVM College of Medicine</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-HL-121706</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Mark T</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All procedures involving animals received prior approval from the University of Vermont Institutional Animal Care and Use Committee (IACUC, protocol # 14-063 and 16-010). Animals were euthanized by intraperitoneal injection of sodium pentobarbital (100 mg/kg) followed by rapid decapitation. Every effort was made to minimize suffering of animal subjects.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting source data files.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Vanlandewijck M</collab><collab>He L</collab><collab>Mäe MA</collab><collab>Andrae J</collab><collab>Ando K</collab><collab>Del Gaudio F</collab><collab>Nahar K</collab><collab>Lebouvier T</collab><collab>Laviña B</collab><collab>Gouveia L</collab><collab>Sun Y</collab><collab>Raschperger E</collab><collab>Räsänen M</collab><collab>Zarb Y</collab><collab>Mochizuki N</collab><collab>Keller A</collab><collab>Lendahl U</collab><collab>Betsholtz C</collab></person-group><year iso-8601-date="2018">2018</year><source>A molecular atlas of cell types and zonation in the brain vasculature.</source><ext-link ext-link-type="uri" xlink:href="http://betsholtzlab.org/VascularSingleCells/database.html">http://betsholtzlab.org/VascularSingleCells/database.html</ext-link><comment>The searchable database is publicly available at http://betsholtzlab.org/VascularSingleCells/database.html. Accession numbers are GSE98816, GSE99058 and GSE99235.</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-38689-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>